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PURPOSE. To assess the association between systemic levels of inflammation-associated
proteins and severe retinopathy of prematurity (ROP) in extremely preterm infants.
METHODS. We collected whole blood on filter paper on postnatal days 1, 7, 14, 21, and 28 from
1205 infants born before the 28th week of gestation, and measured the concentrations of 27
inflammation-associated, angiogenic, and neurotrophic proteins. We calculated odds ratios
with 95% confidence intervals for the association between top quartile concentrations of each
protein and prethreshold ROP.
RESULTS. During the first three weeks after birth, high concentrations of VEGF-R1,
myeloperoxidase (MPO), IL-8, intercellular adhesion molecule (ICAM)-1, matrix metal-
loproteinase 9, erythropoietin, TNF-a, and basic fibroblast growth factor were associated with
an increased risk for prethreshold ROP. On day 28, high levels of serum amyloid A, MPO, IL-6,
TNF-a, TNF-R1/-R2, IL-8, and ICAM-1 were associated with an increased risk. Top quartile
concentrations of the proinflammatory cytokines TNF-a and IL-6 were associated with
increased risks of ROP when levels of neuroprotective proteins and growth factors, including
BDNF, insulin-like growth factor 1, IGFBP-1, VEGFR-1 and -2, ANG-1 and PlGF, were not in the
top quartile. In contrast, high concentrations of NT-4 and BDNF appeared protective only in
infants without elevated inflammatory mediators.
CONCLUSIONS. Systemic inflammation during the first postnatal month was associated with an
increased risk of prethreshold ROP. Elevated concentrations of growth factors, angiogenic
proteins, and neurotrophins appeared to modulate this risk, and were capable of reducing the
risk even in the absence of systemic inflammation.
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Retinopathy of prematurity (ROP) blinds approximately20,000 infants annually.1 The incidence of ROP in high
income countries has remained stable over the last 3 decades,2
but due to increased survival of infants born preterm, the
number of children affected by ROP is rising in low- and middle-
income countries.1 In addition to the risk of a poor visual
outcome, infants with ROP are at increased risk of dysfunctions
associated with nonvisual neural disabilities.3–6 These co-
occurrences suggest a shared etiology with similar risk factors
for retinopathy and brain damage in premature newborns.3,7
In the extremely low gestational age newborn (ELGAN)
study8 systemic inflammation has been associated with
damage to the lung, bowel, and brain.9–11 Increasing evidence
points to an association between neonatal inflammation and
ROP.12–17 The dysregulation of retinal vascular development is
an essential factor in ROP pathogenesis.18 Angiogenesis and
inflammation are closely related, and molecules such as
erythropoietin (EPO); VEGF; insulin-like growth factor-1
(IGF-1); and angiopoietins play multiple roles in neural,
vascular, and inflammatory processes.19–23 The role of these
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proteins in systemic circulation in ROP etiology remains
unclear.18,24,25
To our knowledge, no study has evaluated the risk of ROP in
light of the relationship between potential sources of damage
such as circulating inflammation-related proteins and potential
protectors (e.g., IGF-1 and neurotrophins) during the entire
first neonatal month in a large cohort. The ELGAN study
provides an opportunity to evaluate these relationships.
METHODS
Participants (Table 1)
The ELGAN study is a prospective observational cohort study
of children born before the 28th week of gestation at 1 of 14
participating hospitals in five states in the United States during
the years 2002 through 2004.8 Mothers were approached for
informed consent either upon antenatal admission or shortly
after delivery. A total of 1506 infants born to 1249 mothers
were enrolled. Infants with major birth defects or/and
aneuploidy were excluded. The 1205 children who had at
least one eye exam and one or more blood spots collected
during the first postnatal month comprise the sample for this
report. The institutional review boards of all participating
institutions approved the enrollment and consent processes.
The research presented here adheres to the tenets of the
Declaration of Helsinki.
Newborn Variables (Table 2)
Estimate of gestational age was based on date of embryo
retrieval, intrauterine insemination, or fetal ultrasound before
the 14th week (62%). When any of these were not available,
the estimate was based on fetal ultrasound at week 14 or later
(29%); last menstrual period (7%); or gestational age recorded
in the log of the neonatal intensive care unit (1%). Birth weight
z-score was defined as the number of standard deviations
above or below the median weight of infants of the same
gestational age in a referent samples not delivered for
preeclampsia or fetal indications.26 Infants with birth weight
z-score between2 and1 were defined as moderately growth
restricted, and infants with a z-score below2 were defined as
severely growth restricted.
Eye Exam
Definitions of ROP stages were those accepted by the
International Committee for Classification of Retinopathy of
Prematurity.27 In keeping with guidelines, the first ophthalmo-
logic examination was within the 31st to 33rd postmenstrual
week.28 Follow-up exams were as clinically indicated until
normal vascularization began in zone III, and the most severe
ROP stage was recorded. We focused our analyses on
prethreshold ROP, defined as any ROP in zone I, ROP stage 2
or 3 with plus disease, or ROP stage 3 without plus disease in
zone II.29
Blood Spot Collection and Protein Measurement
Drops of blood were collected on filter paper (Schleicher &
Schuell 903) on postnatal days 1 (range: 1–3 days); 7 (range: 5–
8 days); 14 (range: 12–15 days); 21 (range: 19–23 days); and 28
(range: 26–29). All blood was obtained from the remainder of
specimens obtained for clinical indications. Dried blood spots
were stored at 708C in sealed bags with a desiccant until
processed. Details of the process of elution of protein from
blood spots are provided elsewhere.30 The total protein
concentration in each eluted sample was determined by
bicinchoninic acid assay (Thermo Fisher Scientific, Inc.,
Rockford, IL, USA) using a multi-label counter (Victor 2; Perkin
Elmer, Boston, MA, USA). The concentrations of each protein
listed in Table 3 and measured as detailed below were
normalized to milligrams of total protein.
Protein Biomarker Measurements (Table 3)
All proteins listed in Table 3 were measured at the Genital Tract
Biology Laboratory at the Brigham and Women’s Hospital in
Boston Massachusetts. The procedure is described in detail
elsewhere.31 The laboratory used meso scale discovery
multiplex platform and microplate detection platform (Sector
Imager 2400; Gaithersburg, MD, USA) to measure C-reactive
protein (CRP); serum amyloid A (SAA); myloeperoxidase
(MPO) interleukin (IL)-1b; IL-6, IL-6 Receptor (IL-6R); TNF-a,
TNF receptor-1 (TNF-R1); TNFR-2; IL-8 (CXCL8); regulated
upon activation, normal T-cell expressed, and secreted
(RANTES; CCL5); intercellular adhesion molecule-1 (ICAM-1;
CD54); vascular cell adhesion molecule-1 VCAM-1; CD106);
VEGF; VEGF receptor-1 (VEGFR-1; sFLT-1); VEGFR-2 (KDR);
IGF-1 binding protein-1 (IGFBP-1); thyroid stimulating hor-
mone (TSH); matrix metalloproteinase-9 (MMP-9); and EPO. A
multiplex immunobead assay manufactured By R&D Systems
(Minneapolis, MN, USA) and a commercial reader (MAGPIX
Luminex; R&D Systems) were used to measure angiopoietin 1
(ANG-1); angiopoietin 2 (ANG-2); placenta growth factor
(PlGF); neurotrophin-4 (NT-4); brain-derived neurotrophic
TABLE 1. Sample Description
Yes No
Enrolled 1506
Had one or more blood spots collected 1220 235
Had at least one eye exam 1205 15
Had more than one eye exam 1113 92
Diagnosed prethreshold ROP 168 1037
Blood spot obtained on:
Day 1 1107 98
Day 7 1129 76
Day 14 1024 181
2 of above 3 days (epoch 1) 1141 64
Day 21 935 270
Day 28 877 328
Both of the above 2 days (epoch 2) 766 439
TABLE 2. Characteristics of Infants in the Sample
Prethreshold
Row Number
of Infants
Retinopathy of Prematurity
Yes, % No, %
Sex
Male 54 53 639
Gestational age, wk
23–24 41 18 259
25–26 51 46 559
27 7 36 387
Birth weight z-score
< 2 9 6 75
‡ 2, < 1 22 12 162
‡ 1 69 82 968
Column N 168 1037 1205
Numbers in ‘‘Yes’’ and ‘‘No’’ column are column percent.
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factor (BDNF); and basic fibroblastic growth factor (bFGF).
ELISA (R&D Systems) was used to measure IGF-1.
The concentrations of proteins measured in the ELGAN
Study varied with gestational age category (23–24, 25–26, 27
weeks), and postnatal day of blood collection (1, 7, 14, 21, and
28).30,32 Because we were interested in the contribution of
both high and low concentrations, and the concentrations of
most proteins did not follow a normal distribution, the
distribution of each protein’s concentration was divided into
quartiles.
The proteins included were analyzed in two sets years apart
with an ‘‘early epoch’’ of specimens (days 1, 7, and 14)
measured from 2010 to 2011, and a ‘‘late epoch’’ (days 21 and
28) from 2014 to 2015. Consequently, the two different sets
were analyzed separately. We divided our sample into 30
groups defined by gestational age category (23–24, 25–26, 27
weeks), postnatal day of blood collection (1, 7, 14, 21, and 28),
and measurement set (2009–2010, 2015). The infants were
classified as being in the top quartile or not compared to their
peers in in the same group.
Data Analyses
We tested the hypothesis that infants who had a protein
concentration in the top quartile on each day were no more
likely than their peers to be given a diagnosis of prethreshold
ROP. In this sample, both low gestational age and fetal growth
restriction are associated with protein concentrations,30,33 as
well as with prethreshold ROP.34 Consequently, we adjusted for
gestational age category (23–24, 25–26, 27 weeks) and
birthweight z-score < 1. Stratification by gestational age
would have led to reduced statistical power. We created
logistic regression models to evaluate each biomarker individ-
ually. These models allowed us to calculate odds ratios (OR)
and 95% confidence interval (CI). Risk ratios cannot be
calculated in logistic regression models, and thus cannot adjust
for important confounders such as gestational age and
birthweight.
Early sustained inflammation was defined as a protein
concentration in the top quartile on two or more of the first
three protocol days (days 1, 7, and 14), and late sustained
inflammation was defined as being in the top quartile on both
of the last two protocol days (days 21 and 28). Assessments for
sustained/recurrent inflammation were restricted to children
who had blood collected on 2 or 3 days in the ‘‘early epoch’’,
and on both days in the ‘‘late epoch.’’
High concentrations of neurotrophic and/or angiogenic
proteins have the potential to prevent brain damage and
enhance repair.35 We therefore conducted additional analyses
examining ROP risk in light of the concurrent concentrations
of two proteins, one with pro-inflammatory properties, and
one with neurotrophic properties. In these logistic regression
analyses children who did not have high (i.e., top quartile)
concentrations of either protein were the referent group.
RESULTS
In this sample of infants selected on the basis of gestational age
at birth, the incidence of prethreshold was 27% among
children born during weeks 23 or 24, 14% among children
born during the 25th or 26th weeks, and only 3% among
children born during the 27th week of gestation.
Early Epoch: Days 1, 7, and 14 (Table 4)
The risk of prethreshold ROP risk was increased when day 1
concentrations of VEGFR-1 were in the top quartile and day 14
concentrations of MPO, IL-8, ICAM-1, MMP-9, and EPO were in
the top quartile. In contrast, a reduced ROP risk was associated
with top quartile concentrations of the following: day 1, SAA;
day 7, VEGF and ANG-1; and day-14, RANTES, TSH, BDNF, and
ANG-1. Recurrent/sustained elevated concentrations (i.e.,
being in the top quartile on ‡2 days) of MPO and IL-8 in the
early epoch (i.e., days 1, 7, and 14) were associated with
increased ROP risk. A recurrent/sustained elevated concentra-
tions of RANTES were associated with decreased risk.
Late Epoch: Days 21 and 28 (Table 4)
In the late epoch, an increased risk of prethreshold ROP was
associated with a top quartile of the following proteins: day 21
TNF-a and bFGF, and day 28 SAA, MPO, IL-6, TNF-a, TNF-R1
and -R2, IL-8, and ICAM-1. In contrast, the top quartile
concentrations of BDNF, NT-4 and ANG-1 on day 21 and 28,
and PIGF on day 28 only, were associated with a reduced ROP
risk.
Recurrent/sustained elevated late epoch concentrations
(i.e., in the top quartile on both days 21 and 28) of CRP,
SAA, MPO, IL-6, TNF-R1, TNF-R2, and IL-8 were associated with
increased ROP risk. A reduced risk was associated with
recurrent/sustained elevations of NT-4, BDNF, and ANG-1.
ROP Risk Related to the Co-occurrence of Proteins
on Day 28 (Table 5)
We wanted to study how the co-occurrence of presumed
‘‘protective’’ and ‘‘damaging’’ biomarkers influenced the risk of
prethreshold ROP. In Table 5, the Ang-23 IL-6þ/þgroup has an
OR of 2.0; since the lower bound of 95% CI does not include
1.0, the OR is significantly elevated compared to the referent
group (/) at the P < 0.05 level. Conversely, the NT-4 3 IL-6
(þ/) OR is 0.4; since the upper bound of the 95% CI does not
TABLE 3. Proteins Measured on Days 1, 7, 14, 21, and 28
CRP C-reactive protein
SAA Serum amyloid A
MPO Myeloperoxidase
IL-1b Interleukin 1b
IL-6 Interleukin 6
IL-6R Interleukin 6 Receptor
TNF-a Tumor necrosis factor a
TNF-R1 Tumor necrosis factor receptor 1
TNF-R2 Tumor necrosis factor receptor 2
IL-8; CXL8 Interleukin-8
RANTES; CCL5 Regulated upon activation, normal T-cell expressed,
and secreted
ICAM-1 Intercellular attracting molecule-1
VCAM-1 Vascular cell attracting molecule-1
MMP-9 Matrix metalloproteinase
TSH Thyroid-stimulating hormone
EPO Erythropoietin
bFGF Basic fibroblast growth factor
IGF-1 Insulin-like growth factor 1
IGFBP-1 Insulin-like growth factor binding protein 1
VEGF Vascular endothelial growth factor
VEGFR-1 Vascular endothelial growth factor receptor 1
VEGFR-2 Vascular endothelial growth factor receptor 2
ANG-1 Angiopoietin 1
ANG-2 Angiopoietin 2
PlGF; PGF Placental growth factor
NT-4 Neurotrophin-4
BDNF Brain-derived neurotrophic factor
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include 1.0, the OR is significantly reduced compared to the
referent group (/) at the P < 0.05 level.
On day 28, the ROP risk was reduced when the neurotropic
factors NT-4 and/or BDNF were in the top quartile, but this risk
reduction was observed only when the three inflammation-
related proteins, IL-6, TNF-a, and ICAM-1, were in the lower
three quartiles. This pattern was also observed for PIGF, but
only for the inflammation-related protein ICAM-1. In contrast,
when the concentration of TNF-a was in the top quartile, the
risk of ROP was significantly elevated only when the
concentrations of IGF-1, IGFBP-1, VEGF, VEGFR-1, VEGFR-2,
ANG-1, ANG-2, or PIGF were not in the top quartile. A
heightened ROP risk was also observed when IL-6 was in the
top quartile simultaneously with a top quartile of ANG-2 or
VEGFR-2 in the lower three quartiles. Top concentrations of
ICAM-1 were associated with increased risk of ROP only when
VEGFR-2 concentrations were in the lower 3 quartiles.
ROP Risk Related to the Co-Occurrence of Proteins
on Both Days 21 and 28 (Table 6)
Because persisting or recurrent inflammation appears to be
more damaging than just isolated incidences of inflamma-
tion,36,37 we also studied the relationships between top
quartile concentrations on two separate days a week apart.
Infants who had top quartile concentrations of NT-4, BDNF,
and ANG-1 on both days of the late epoch were at reduced risk
of ROP when the selected inflammation-related protein (IL-6,
TNF-a, or ICAM-1) was not in the top quartile on both days.
Children who had a top quartile concentration of IL-6 on both
days were at increased risk of ROP when the concentration of
the neurotrophic protein (BDNF, IGF-1, IGFBP-1, VEGF, VEGFR-
1 and 2, ANG-1, or PIGF) was not in the top quartile on both
days. Similarly, top concentrations of ICAM-1 were associated
with increased risk of ROP only when VEGFR-2 concentrations
were in the lower three quartiles. A heightened ROP risk was
also observed when IL-6 was in the top quartile simultaneously
with a top quartile of ANG-2.
DISCUSSION
Three of our findings are worthy of discussion. First, we found
an increased ROP risk when some of the inflammation-related
proteins were elevated. Second, infants who had top quartile
concentrations of proteins with angiogenic and/or neurotroph-
ic properties were at reduced risk of ROP, most prominently in
the 3rd and 4th postnatal weeks (the late epoch). Third, there
was a modulatory interaction between levels of proinflamma-
tory proteins (e.g., IL-6, TNF-a, and ICAM-1) and a number of
neuroprotective proteins. For some proteins (e.g., VEGFR-2,
IGF-1) the protective effects were only apparent when we
stratified the sample by the co-occurrence of a top concentra-
tion of the proteins associated with increased ROP risk (e.g., IL-
6, TNF-a, and ICAM-1).
TABLE 4. Odds Ratios (95% CI) for Prethreshold ROP (Number of infants, n¼ 168) Comparing Children With a Top Quartile Concentration of the
Protein on the Left on Each Postnatal Day to Children in the Same Gestational Age Category Who Had a Concentration in the Lower Three Quartiles
on the Corresponding Day
Early Epoch Late Epoch
Day 1 Day 7 Day 14 ‡ 2 Days Day 21 Day 28 Day 21 & 28
n ¼1107 n ¼ 1129 n ¼ 1024 n ¼ 1141 n ¼ 935 n ¼ 877 n ¼ 766
CRP 0.7 (0.5, 1.1) 1.3 (0.9, 1.9) 1.1 (0.7, 1.7) 1.0 (0.7, 1.6) 1.2 (0.8, 1.9) 1.3 (0.9, 2.0) 2.0 (1.1, 3.5)
SAA 0.6 (0.4, 0.9) 0.9 (0.6, 1.3) 1.2 (0.8, 1.7) 0.9 (0.5, 1.4) 1.3 (0.9, 2.0) 1.6 (1.05, 2.5) 2.4 (1.4, 4.3)
MPO 0.9 (0.6, 1.4) 1.3 (0.9, 1.9) 1.7 (1.1, 2.4) 1.5 (1.02, 2.4) 1.4 (0.9, 2.1) 1.8 (1.2, 2.8) 1.8 (1.05, 3.1)
IL-1b 1.0 (0.7, 1.5) 0.8 (0.6, 1.3) 1.3 (0.9, 2.0) 0.9 (0.6, 1.5) 1.2 (0.8, 1.8) 1.1 (0.7, 1.7) 0.8 (0.4, 1.5)
IL-6 1.2 (0.8, 1.8) 1.2 (0.8, 1.7) 1.2 (0.8, 1.8) 1.2 (0.8, 1.9) 1.4 (0.9, 2.1) 1.6 (1.1, 2.4) 2.1 (1.2, 3.6)
IL-6R 0.9 (0.6, 1.4) 1.0 (0.6, 1.4) 1.3 (0.9, 2.0) 1.3 (0.8, 2.0) 1.3 (0.9, 2.0) 1.4 (0.9, 2.1) 1.5 (0.9, 2.6)
TNF-a 1.2 (0.8, 1.8) 1.0 (0.7, 1.5) 1.5 (0.97, 2.2) 1.2 (0.8, 1.8) 1.5 (1.01, 2.3) 1.7 (1.1, 2.6) 1.3 (0.8, 2.1)
TNF-R1 1.1 (0.7, 1.7) 1.2 (0.8, 1.7) 1.5 (1.00, 2.2) 1.4 (0.95, 2.2) 1.3 (0.8, 2.0) 2.1 (1.4, 3.2) 2.0 (1.1, 3.5)
TNF-R2 1.1 (0.7, 1.6) 0.9 (0.6, 1.4) 1.4 (0.9, 2.0) 1.2 (0.8, 1.9) 1.5 (0.98, 2.2) 1.6 (1.1, 2.5) 2.1 (1.2, 3.6)
IL-8 0.8 (0.5, 1.2) 1.4 (0.96, 2.1) 2.3 (1.6, 3.4) 2.0 (1.3, 3.0) 1.4 (0.9, 2.1) 2.0 (1.3, 3.0) 1.9 (1.1, 3.2)
RANTES 0.7 (0.5, 1.1) 0.7 (0.4, 1.03) 0.5 (0.3, 0.9) 0.6 (0.3, 0.9) 0.7 (0.5, 1.1) 0.7 (0.5, 1.2) 0.6 (0.3, 1.3)
ICAM-1 0.8 (0.5, 1.2) 1.2 (0.8, 1.8) 1.8 (1.2, 2.6) 1.5 (1.00, 2.3) 1.4 (0.95, 2.2) 1.7 (1.1, 2.5) 1.6 (0.97, 2.6)
VCAM-1 0.9 (0.6, 1.4) 1.0 (0.7, 1.5) 0.8 (0.5, 1.2) 1.0 (0.6, 1.5) 0.9 (0.6, 1.3) 0.6 (0.4, 1.01) 1.0 (0.5, 1.8)
MMP-9 0.9 (0.6, 1.4) 1.1 (0.7, 1.6) 1.5 (1.04, 2.3) 1.3 (0.8, 2.1) 1.4 (0.9, 2.1) 1.3 (0.8, 2.0) 1.8 (0.98, 3.2)
TSH 1.1 (0.7, 2.6) 0.9 (0.6, 1.4) 0.6 (0.4, 0.9) 0.7 (0.4, 1.1) 1.1 (0.7, 1.7) 0.9 (0.6, 1.5) 1.2 (0.7, 2.1)
EPO 1.0 (0.7, 1.5) 1.1 (0.8, 1.7) 1.9 (1.3, 2.7) 1.4 (0.9, 2.1) 0.9 (0.6, 1.4) 1.1 (0.7, 1.7) 1.1 (0.6, 1.9)
NT-4 0.8 (0.5, 1.2) 0.7 (0.4, 1.02) 1.0 (0.7, 1.5) 0.8 (0.5, 1.3) 0.5 (0.3, 0.8) 0.4 (0.3, 0.8) 0.3 (0.1, 0.8)
BDNF 1.0 (0.6, 1.5) 0.9 (0.6, 1.3) 0.5 (0.3, 0.9) 0.8 (0.5, 1.2) 0.5 (0.3, 0.8) 0.4 (0.2, 0.7) 0.2 (0.1, 0.6)
bFGF 1.1 (0.8, 1.7) 1.0 (0.6, 1.4) 1.3 (0.8, 1.9) 1.1 (0.7, 1.8) 1.6 (1.5, 2.4) 1.2 (0.8, 1.9) 1.4 (0.8, 2.5)
IGF-1 1.0 (0.6, 1.5) 1.0 (0.6, 1.5) 1.0 (0.7, 1.6) 0.9 (0.6, 1.5) 1.3 (0.9, 2.0) 0.7 (0.4, 1.1) 0.9 (0.5, 1.5)
IGFBP-1 0.9 (0.6, 1.4) 1.3 (0.9, 2.0) 0.9 (0.6, 1.4) 1.2 (0.7, 1.8) 0.8 (0.5, 1.3) 1.0 (0.7, 1.6) 0.6 (0.3, 1.3)
VEGF 0.9 (0.6, 1.3) 0.6 (0.4, 0.9) 1.0 (0.7, 1.5) 0.7 (0.5, 1.1) 1.0 (0.6, 1.5) 0.7 (0.5, 1.2) 0.8 (0.4, 1.5)
VEGFR-1 1.5 (1.1, 2.3) 1.2 (0.8, 1.7) 1.0 (0.7, 1.5) 1.4 (0.9, 2.1) 1.2 (0.8, 1.8) 0.8 (0.5, 1.3) 0.8 (0.4, 1.5)
VEGFR-2 0.6 (0.4, 1.00) 1.0 (0.7, 1.5) 1.2 (0.8, 1.7) 0.8 (0.5, 1.2) 1.1 (0.8, 1.8) 0.8 (0.5, 1.2) 0.9 (0.5, 1.7)
PIGF 1.3 (0.9, 1.9) 0.8 (0.5, 1.2) 1.1 (0.7, 1.7) 0.9 (0.6, 1.4) 0.7 (0.4, 1.1) 0.6 (0.3, 0.9) 0.7 (0.3, 1.5)
ANG-1 0.8 (0.5, 1.3) 0.6 (0.4, 0.97) 0.6 (0.4, 0.9) 0.7 (0.4, 1.1) 0.5 (0.3, 0.9) 0.5 (0.3, 0.9) 0.2 (0.1, 0.6)
ANG-2 0.8 (0.5, 1.2) 1.0 (0.7, 1.5) 1.2 (0.8, 1.8) 0.9 (0.6, 1.5) 1.2 (0.8, 1.9) 1.3 (0.8, 2.0) 1.5 (0.9, 2.4)
All analyses are adjusted for gestational age and birthweight z-score <1. The last column of each epoch represents an elevated concentration
on 2 or more of the days in the present epoch. Bold indicates odds ratios significantly >1 (P < 0.05) and bold italic indicates odds ratios significantly
<1 (P < 0.05).
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The pathogenesis of ROP is classically described as a 2-
phase disruption of the retinal vascular development, where
the first phase is characterized by cessation of retinal vessel
formation and maturation, while new and aberrant vessel
formation and growth occurs in the second phase. Prenatal
phenomena have the potential to sensitize the developing
retina, and subsequent postnatal stimuli/exposures together
might constitute a ‘‘prephase’’ of ROP.12
We found that elevated concentrations of inflammatory
mediators during the latter part of the first postnatal month
(days 14–28) were most predictive of later ROP. As the second
phase of ROP begins close to weeks 30 to 32 and the
gestational age of the infants in our cohort varies, most of our
protein concentration measurements were from specimens
obtained before neovascularization begins or very early during
neovascularization. Our findings thereby support the concept
of a prephase that precedes phase 1.
Inflammation Is a Risk Factor for Prethreshold
ROP
We identified TNF-a, TNF-R1, TNF-R2, IL-6, IL-8, SAA, CRP,
ICAM-1, and MPO as proteins with potential to increase ROP
risk. SAA and CRP are well-established liver-derived markers of
systemic inflammation.38 TNF-a, and IL-6 are cytokines acting
as primary initiators of inflammation following infection or
tissue damage, activating macrophages and T-cells, as well as
inducing angiogenesis and apoptosis.39 In the retina, TNF-a is
involved in proliferative retinopathies as well as inflammatory
diseases,40 and high plasma concentrations of IL-6, IL-8, and
TNF-a have been associated with increased risk of ROP.17,41
Soluble TNF-receptors has potential to increase the half-life of
TNF-a in the blood circulation.42 The inflammatory response
includes upregulation of effector molecules such as chemo-
kines (e.g., IL-8, RANTES), and adhesion molecules (e.g., ICAM-
1).43 Because low vitreous and blood concentrations of
RANTES have been found in children who developed severe
ROP,17,44,45 RANTES might play a protective role. Our finding
that high RANTES concentrations were associated with lower
risk, although only in the early epoch, supports this inference.
Neurotrophic Proteins Appear to Protect Against
ROP
We found a variety of biomarkers associated with reduced ROP
risk, including IGF-1; angiopoietin (ANG-1); and neurotrophins
(NT-4 and BDNF). These molecules are referred to as
angioneurins, and are capable of both neural and vascular
protection and repair.22 Top-quartile concentrations of ANG-1
most consistently predicted reduced ROP risk on all days,
except day 1. Both ANG-1 and ANG-2 are vascular growth
factors important both in fetal life and after birth, where they
TABLE 5. Odds ratios (95% CI) for Prethreshold ROP Comparing Children With (þ) and Without () a Top Quartile Blood Concentration of Each of
Two Proteins
IL-6 TNF-a ICAM-1
þ  þ  þ 
NT-4
þ 0.8 (0.3, 2.0) 0.4 (0.2, 0.8) 0.9 (0.3, 2.3) 0.4 (0.2, 0.8) 1.1 (0.5, 2.4) 0.3 (0.2, 0.6)
 1.5 (0.9, 2.3) 1.0 1.6 (1.00, 2.5) 1.0 1.3 (0.8, 2.1) 1.0
BDNF
þ 0.6 (0.2, 1.7) 0.4 (0.2, 0.8) 0.9 (0.4, 2.1) 0.4 (0.2, 0.7) 0.6 (0.1, 1.9) 0.4 (0.2, 0.8)
 1.5 (0.96, 2.4) 1.0 1.6 (1.00, 2.5) 1.0 1.4 (0.9, 2.3) 1.0
IGF-1
þ 1.0 (0.4, 2.4) 0.7 (0.4, 1.3) 1.1 (0.5, 2.7) 0.7 (0.4, 1.3) 1.6 (0.7, 3.5) 0.6 (0.3, 1.01)
 1.6 (1.00, 2.5) 1.0 1.7 (1.1, 2.7) 1.0 1.3 (0.8, 2.1) 1.0
IGFBP-1
þ 1.6 (0.8, 2.9) 0.9 (0.5, 1.5) 1.8 (0.8, 3.8) 1.0 (0.6, 1.7) 1.5 (0.8, 2.8) 0.9 (0.5, 1.7)
 1.5 (0.9, 2.5) 1.0 1.7 (1.1, 2.8) 1.0 1.5 (0.9, 2.6) 1.0
VEGF
þ 1.5 (0.7, 3.2) 0.7 (0.4, 1.2) 0.9 (0.3, 2.2) 1.0 (0.6, 1.7) 0.9 (0.4, 2.2) 0.9 (0.5, 1.6)
 1.4 (0.9, 2.3) 1.0 2.0 (1.3, 3.2) 1.0 1.7 (1.1, 2.7) 1.0
VEGFR-1
þ 1.2 (0.5, 2.5) 0.8 (0.5, 1.5) 1.1 (0.5, 2.4) 0.9 (0.5, 1.6) 1.3 (0.7, 2.5) 0.7 (0.4, 1.3)
 1.6 (1.00, 2.6) 1.0 1.9 (1.2, 3.1) 1.0 1.5 (0.9, 2.5) 1.0
VEGFR-2
þ 1.0 (0.5, 2.2) 0.8 (0.4, 1.4) 1.1 (0.5, 2.2) 0.8 (0.4, 1.4) 1.1 (0.6, 1.9) 0.6 (0.3, 1.2)
 1.7 (1.03, 2.7) 1.0 2.0 (1.2, 3.2) 1.0 1.9 (1.1, 3.3) 1.0
ANG-1
þ 0.9 (0.4, 2.0) 0.5 (0.3, 1.02) 1.0 (0.4, 2.3) 0.5 (0.3, 1.01) 0.9 (0.3, 2.6) 0.6 (0.3, 1.00)
 1.6 (0.98, 2.5) 1.0 1.7 (1.1, 2.7) 1.0 1.4 (0.9, 2.3) 1.0
ANG-2
þ 2.0 (1.2, 3.6) 0.9 (0.5, 1.6) 1.8 (0.9, 3.3) 1.3 (0.7, 2.2) 1.5 (0.9, 2.7) 1.2 (0.7, 2.2)
 1.2 (0.7, 2.1) 1.0 1.8 (1.1, 3.0) 1.0 1.7 (0.96, 2.9) 1.0
PIGF
þ 1.0 (0.4, 2.2) 0.5 (0.3, 1.01) 1.1 (0.5, 2.4) 0.5 (0.3, 1.02) 1.2 (0.6, 2.7) 0.5 (0.2, 0.9)
 1.5 (0.95, 2.4) 1.0 1.7 (1.04, 2.7) 1.0 1.4 (0.8, 2.2) 1.0
Measured on postnatal day 28 to children without a top quartile concentration of both proteins. The quartiles were determined within
gestational age category and the day the blood was obtained. In these analyses, 4 groups are formed by the 2-protein combinations (i.e.,þ/þ,þ/,/
þ,/). The/ group serves as the referent group for the other three. All analyzes are adjusted for gestational age and birth weight z-score <1.
Bold indicates odds ratios significantly >1 (P < 0.05) and bold italic indicates odds ratios significantly < 1 (P < 0.05).
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remodel the developing vasculature. Both are ligands of the
Tie2 receptor, although one is in an agonist (ANG-1) and the
other an antagonist (ANG-2). Whereas ANG-1 promotes
vascular maturation and stability, ANG-2 initiates vessel
instability and neovascularization.46,47 Our study further
emphasizes ANG-1 as a possible protector throughout the
whole prephase and phase 1 of ROP.
Neurotrophins belong to a family of growth factors that
promote neuronal as well as oligodendrocyte survival and
differentiation both in the central and peripheral nervous
systems.48,49 Although the focus has been on the ability of
neurotrophins to protect and repair the neural system, they
can also have a beneficial effect on the vascular system.22,50 We
found that high concentrations of the neurotrophins NT-4 and
BDNF were associated with a reduced risk for prethreshold
ROP. This is in keeping with other studies where low serum
concentrations of NT-4 and BDNF were associated with an
increased ROP risk.17,51
We found a top quartile concentration of VEGF on day 7
only to be associated with a reduced ROP risk. In the setting of
top quartile concentrations of TNF-a, IL-6, and ICAM-1 on days
21 and 28, top quartile concentrations of VEGF on those days
were associated with lower risks of ROP than observed when
VEGF concentrations were lower. These findings are probably
reflective of what is seen in the retina, with suppression of
VEGF expression during the first hypoxic phase of ROP, which
coincides with the timing of the samples tested in this study.
After the first phase, VEGF expression is upregulated and
potentiated by growth factors such as IGF-1, resulting in
proliferative ROP. It is at this point that intravitreous anti-VEGF
agents can be given to effectively treat severe ROP.52–54 VEGF
production can be stimulated by hypoxia, but systemic
diseases, oxygen treatment and respiratory distress might also
trigger VEGF production and release.55 From this we infer that
maintenance of higher VEGF levels during the ROP prephase
or phase 1 would be reflective of less vasocessation, and thus
might reduce ROP risk.
Looking at Inflammation and Protection
Simultaneously
We examined the risk of ROP associated with concurrent high
concentrations of inflammation-associated proteins and high
concentrations of proteins with neurotrophic and/or angio-
genic properties (angioneurins). This reflects our perception
that one can best identify the contribution of an angioneurin in
the presence of high concentrations of an inflammation-related
protein, and that the contribution of high concentrations of an
inflammation-related protein is most easily identified when the
concentrations of angioneurins are low.
The most common pattern we found was characterized by
an increased ROP risk when the concentration of an
TABLE 6. Odds Ratios (95% CI) for Prethreshold ROP Comparing Children With (þ) and Without () a Top Quartile Blood Concentration of Each of
Two Proteins Measured on Both Postnatal Days 21 and 28 to Children Without a Top Quartile Concentration of Both Proteins on Both Days
IL-6 TNF-a ICAM-1
þ  þ  þ 
NT-4
þ 3.3 (0.6, 18) 0.2 (0.1, 0.6) 0.3 (0.03, 2.2) 0.3 (0.1, 0.8) 0.6 (0.1, 2.9) 0.3 (0.1, 0.7)
 1.7 (0.97, 3.0) 1.0 1.2 (0.7, 2.0) 1.0 1.4 (0.8, 2.4) 1.0
BDNF
þ – 0.3 (0.1, 0.8) – 0.3 (0.1, 0.9) – 0.3 (0.1, 0.8)
 2.1 (1.2, 3.6) 1.0) 1.3 (0.8, 2.1) 1.0 1.4 (0.8, 2.4) 1.0
IGF-1
þ 1.0 (0.1, 8.2) 1.0 (0.5, 1.7) 0.7 (0.2, 2.6) 0.9 (0.5, 1.7) 2.2 (0.8, 6.2) 0.7 (0.3, 1.3)
 2.1 (1.2, 3.7) 1.0 1.2 (0.7, 2.2) 1.0 1.2 (0.7, 2.1) 1.0
IGFBP-1
þ 1.0 (0.2, 4.8) 0.5 (0.2, 1.4) – 0.7 (0.2, 1.5) 0.5 (0.1, 2.2) 0.7 (0.3, 1.9)
 2.1 (1.2, 3.7) 1.0 1.2 (0.7, 2.0) 1.0 1.7 (0.97, 2.8) 1.0
VEGF
þ 1.0 (0.1, 8.0) 1.0 (0.5, 1.9) 0.6 (0.1, 2.7) 1.0 (0.5, 2.0) 1.0 (0.2, 4.9) 0.9 (0.4, 1.8)
 2.1 (1.2, 3.7) 1.0 1.2 (0.8, 2.2) 1.0 1.5 (0.9, 2.5) 1.0
VEGFR-1
þ 2.0 (0.5, 8.5) 0.8 (0.4, 1.6) 0.7 (0.2, 2.5) 0.9 (0.4, 1.9) 1.1 (0.3, 4.4) 0.9 (0.4, 1.7)
 2.0 (1.1, 3.5) 1.0 1.3 (0.7, 2.2) 1.0 1.4 (0.8, 2.5) 1.0
VEGFR-2
þ 1.7 (0.5, 5.5) 0.9 (0.4, 1.7) 0.6 (0.2, 2.0) 1.2 (0.6, 2.3) 0.8 (0.4, 2.0) 1.2 (0.6, 2.7)
 2.1 (1.2, 3.7) 1.0 1.4 (0.8, 2.4) 1.0 1.9 (1.02, 3.4) 1.0
ANG-1
þ 0.5 (0.1, 4.1) 0.3 (0.1, 0.8) 0.3 (0.04, 2.2) 0.3 (0.1, 0.8) 0.6 (0.1, 5.1) 0.3 (0.1, 0.7)
 2.1 (1.2, 3.6) 1.0 1.2 (0.7, 2.0) 1.0 1.3 (0.8, 2.3) 1.0
ANG-2
þ 2.9 (1.3, 6.6) 1.1 (0.6, 2.1) 1.4 (0.6, 3.5) 1.5 (0.8, 2.6) 1.4 (0.6, 3.0) 1.6 (0.9, 3.1)
 1.7 (0.9, 3.4) 1.0 1.2 (0.7, 2.1) 1.0 1.7 (0.9, 3.1) 1.0
PIGF
þ 2.9 (0.2, 34) 0.7 (0.3, 1.7) 0.3 (0.04, 2.7) 0.9 (0.4, 2.2) 0.9 (0.1, 7.2) 0.8 (0.3, 1.8)
 2.0 (1.1, 3.4) 1.0 1.3 (0.8, 2.2) 1.0 1.5 (0.9, 2.4) 1.0
The quartiles were determined within gestational age category and the day the blood was obtained. In these analyses, 4 groups are formed by the
2-protein combinations (i.e., þ/þ, þ/, /þ, /). The / group serves as the referent group for the other three. All analyses are adjusted for
gestational age and birth weight Z–score < 1. Bold indicates odds ratios significantly > 1 (P < 0.05) and bold italic indicates odds ratios
significantly < 1 (P < 0.05).
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inflammation-related protein was elevated, and the concentra-
tion of an angioneurin was not. One way to interpret this is
that high concentrations of the inflammation-associated
protein do not elevate ROP risk if the angioneurins are
simultaneously high. Inversely top quartile late epoch concen-
trations of NT-4 and BDNF appeared protective only in the
absence of elevated inflammatory mediators (e.g., IL-6, TNF-a
and ICAM-1). Systemic inflammation has the ability to decrease
gene expression of BDNF in mice.56 In the ELGAN study,
infants who developed systemic inflammation were more likely
to have higher neurotrophin concentrations than their peers
with no systemic inflammation.57 Also in this sample, elevated
concentrations of VEGF, VEGFR-1, VEGFR-2, PlGF, ANG-1, and
ANG-2 were associated with same-day elevated concentrations
of inflammation-related proteins, each other, as well as with
proteins that have neurotrophic properties.58 One explanation
for the co-occurrence of elevated concentrations of inflamma-
tion-related, angiogenic, and neurotrophic factors (potential
protectors) is that a common antecedent upregulates all of
them.59 Another is that one response (probably inflammation)
upregulates the other (protection) as a ‘‘self-defense’’ mecha-
nism. Without additional data about protein response dynamics
it is impossible to distinguish between the two options, but we
think that the ‘‘self-defense’’ hypothesis is supported by our
finding effects of one in the absence of the other (i.e., a risk
increase with inflammation in the absence of elevated
concentrations of protectors, and a risk decrease with elevated
concentrations of protectors in the absence of inflammation;
Tables 5 and 6). When analyzed individually, IGF-1, IGFPB-1,
and VEGFR-2 showed no evidence of protection (Table 4).
However, when high concentrations of these proteins are
evaluated in light of the concentrations of IL-6, TNF-a, and
ICAM-1, risk modulation was identified. We encourage others
to use this strategy. Top concentrations of the three proteins
were not risk-defining in the absence of inflammation, but the
damage caused by inflammatory proteins appeared to increase
ROP risk only when these proteins failed to be elevated. This
suggests a primary role in repair, but also the possibility that
inflammatory mediators (e.g., IL-6 and TNF-a), downregulate
these proteins as one of the mechanisms of inflammation-
driven damage to the retina.
IGF-1 is important for fetal growth, including healthy retinal
angiogenesis. IGF-1 is also probably necessary for normal VEGF
function.60 Low systemic serum IGF-1 concentrations are
associated with increased risk of ROP, and have been used to
identify infants at risk of developing ROP.60–63 Hence,
exogenous IGF-1 supplements have been suggested as a
potential prophylaxis for ROP.24 Interestingly, lower plasma
concentrations of IGF-1 binding protein (IGFBP-3) were found
in infants developing severe ROP.64 We did not find elevated
concentrations of IGF-1 or IGFBP-1 to reduce the risk of ROP in
the absence of inflammation as defined in this study.
We view inflammation as a complex phenomenon that
includes many proteins from multiple functional categories
affecting multiple systems.65–67 The individual inflammation-
related proteins measured are probably surrogates for many
unmeasured proteins involved in inflammatory processes. The
angioneurins included here (including IGF-1) are surrogates for
many unmeasured proteins involved in retinal maturation and
repair. Consequently, exogenous IGF-1 might not be able to
achieve all that is needed to enhance retinal maturation and
repair. On the other hand, we did find infants in the lower
three IGF-1/IGFBP-1 quartiles to be vulnerable when concen-
trations of the inflammatory mediators IL-6 and TNF-a where
elevated. This is in keeping with the finding that inflammation
might be a factor that reduces the already limited IGF-1
production in the preterm newborn.68
Strengths and Limitations
Our study has several strengths. First, we obtained multiple
blood spots weekly during the first postnatal month. The
multiphased development of ROP underscores the importance
of assessing biomarker concentrations longitudinally, as differ-
ent biomarkers probably play different roles in the different
phases of the disease. Second, we measured the concentrations
of a diverse set of proteins, including cytokines, chemokines,
adhesion molecules, a matrix metalloproteinase, and a diverse
set of growth factors. Third, we included more than 1000
infants, making it unlikely that we have missed important
associations due to lack of statistical power, or claimed
associations that might have reflected the instability of small
numbers. Fourth, the infants were selected based on gesta-
tional age, not birth weight, in order to minimize confounding
due to factors related to fetal growth restriction.69 Fifth, we
collected all of our data prospectively, thereby minimizing bias.
Finally, our protein data are of high quality,70,71 and have high
content validity.30,72–74
Our study also has limitations. As the blood–retinal barrier
surrounds the eyes, the concentrations of cytokines and
growth factors in blood do not necessarily reflect the levels
found in the retina and vitreous of the eye.75 On the other
hand, inflammation appears capable of reducing the effective-
ness of these barriers,76 making it difficult to estimate to what
extent circulating proteins influence the retina directly. Our
blood specimens were collected at time points in the early
postnatal period, corresponding to the prephase and 1st phase
of ROP. Subsequently, any biomarker levels or differences that
may occur later, at the time of phase 2 and maximal ROP
development, are still unknown.
The blood we measured was not whole blood, plasma, or
serum. Rather, we eluted blood that had been dropped or
blotted on filter paper. Because some spots are thicker than
others, we normalized our measurements to milligram of total
protein in the eluent. Since this is not equivalent to
measurements made in freshly obtained blood, our measure-
ments are not directly comparable to measurements obtained
from clinical laboratories. Therefore, we do not provide
picograms of each protein per milligram of total protein.
Moreover, we compared the concentrations of each protein
among children who are comparable by virtue of gestational
age group, the day the specimen was collected, and the year
measurements were made. Because the concentrations varied
with each of these, offering a number for each concentration
would be highly misleading.
In conclusion, we found that blood concentrations of
proteins related to inflammation and growth during the first
postnatal month convey information about ROP risk. Top
quartile concentrations of inflammatory mediators were
identified as risk factors for development of prethreshold
ROP, while the top quartile concentrations of proteins with
known angiogenic and neurotrophic properties were associat-
ed with a reduced ROP risk. This study adds to our knowledge
of the complex etiology of ROP development, and is, as far as
we know, the first study with such a wide variety of systemic
biomarkers in a large cohort of extremely low gestational age
newborns.
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